Clinical Influences of Anticentromere Antibody on Primary Sjögren's Syndrome in a Prospective Korean Cohort

Overview

Journal Korean J Intern Med

Specialty General Medicine

Date 2020 Aug 25

PMID 32829574

Citations 8

Authors

Youngjae Park

Jennifer Lee

Jung Hee Koh

Jung Yoon Choe

Yoon-Kyoung Sung

Shin-Seok Lee

Ji-Min Kim

Sung-Hwan Park

Seung-Ki Kwok

Affiliations

Soon will be listed here.

Abstract

Background/aims: This study was performed to clarify influences of anticentromere antibody (ACA) on clinical phenotypes of primary Sjögren's syndrome (pSS) patients in Korea.

Methods: We assessed 318 patients who met the 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for pSS. All patients were selected from the Korean Initiative of primary Sjögren's Syndrome (KISS), a prospective cohort. Among them, 53 patients were positive for ACA, while another 265 patients were not. We compared various clinical data including demographic features, extra-glandular manifestations (EGMs), clinical indices, and laboratory values available from the KISS database between the two groups.

Results: Patients in the ACA-positive pSS group were older (p = 0.042), and had higher xerostomia inventory scores (p = 0.040), whereas glandular dysfunction represented with Schirmer I test was more severe in the ACA-negative group. More frequent Raynaud's phenomenon and liver involvement (both p < 0.001) and less articular involvement (p = 0.037) were observed among the EGMs in the ACA-positive group. Less frequency of leukopenia (p = 0.021), rheumatoid factor (p < 0.001), anti-Ro/SSA antibody positivity (p < 0.001), and hypergammaglobulinemia (p = 0.006), as well as higher positivity rates of anti-nuclear antibody and anti-topoisomerase antibody (p < 0.001 and p = 0.006, respectively) were found in the laboratory data in the ACA-positive pSS group.

Conclusion: Considering distinct phenotypes in hematological and serological features and EGMs, we should monitor the occurrence of these clinical features among pSS patients with ACA in caution.

Citing Articles

Associations between metabolic disorders and Sjögren's disease.

Iwaya C, Iwata J Jpn Dent Sci Rev. 2024; 60:232-238.

PMID: 39502167 PMC: 11535258. DOI: 10.1016/j.jdsr.2024.06.002.

Immunoglobulin G4 in primary Sjögren's syndrome and IgG4-related disease - connections and dissimilarities.

Maslinska M, Kostyra-Grabczak K Front Immunol. 2024; 15:1376723.

PMID: 39364411 PMC: 11446744. DOI: 10.3389/fimmu.2024.1376723.

Anti-centromere antibody positivity is an independent variable associated with salivary gland ultrasonography score in Sjögren's syndrome.

Shimizu T, Nishihata S, Nakamura H, Takagi Y, Sumi M, Kawakami A Sci Rep. 2024; 14(1):5303.

PMID: 38438461 PMC: 10912294. DOI: 10.1038/s41598-024-55767-2.

[Clinical and immunological features of primary Sjögren's syndrome patients with positive anti-centromere protein B antibody].

Meng Y, Chen Y, Zhou P Beijing Da Xue Xue Bao Yi Xue Ban. 2023; 55(6):1088-1096.

PMID: 38101794 PMC: 10723979.

Prevalence and Clinical Implications of Scleroderma-Specific Autoantibodies in Seronegative Patients with Sicca Complaints.

Marketos N, Mavragani C Mediterr J Rheumatol. 2023; 34(3):398-402.

PMID: 37941855 PMC: 10628869. DOI: 10.31138/mjr.20230808.pa.

References

Bournia V, Vlachoyiannopoulos P . Subgroups of Sjögren syndrome patients according to serological profiles. J Autoimmun. 2012; 39(1-2):15-26. DOI: 10.1016/j.jaut.2012.03.001. View

Tsianos E, Hoofnagle J, Fox P, Alspaugh M, Jones E, Schafer D . Sjögren's syndrome in patients with primary biliary cirrhosis. Hepatology. 1990; 11(5):730-4. DOI: 10.1002/hep.1840110504. View

Bournia V, Diamanti K, Vlachoyiannopoulos P, Moutsopoulos H . Anticentromere antibody positive Sjögren's Syndrome: a retrospective descriptive analysis. Arthritis Res Ther. 2010; 12(2):R47. PMC: 2888196. DOI: 10.1186/ar2958. View

Daniels T, Cox D, Shiboski C, Schiodt M, Wu A, Lanfranchi H . Associations between salivary gland histopathologic diagnoses and phenotypic features of Sjögren's syndrome among 1,726 registry participants. Arthritis Rheum. 2011; 63(7):2021-30. PMC: 3128201. DOI: 10.1002/art.30381. View

Yang W, Yu J, Nakajima A, Neuberg D, Lindor K, Bloch D . Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure?. Clin Gastroenterol Hepatol. 2004; 2(12):1116-22. DOI: 10.1016/s1542-3565(04)00465-3. View

Vitali C, Palombi G, Baldini C, Benucci M, Bombardieri S, Covelli M . Sjögren's Syndrome Disease Damage Index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjögren's syndrome, derived from an analysis of a cohort of Italian patients. Arthritis Rheum. 2007; 56(7):2223-31. DOI: 10.1002/art.22658. View

Montano-Loza A, Crispin-Acuna J, Remes-Troche J, Uribe M . Abnormal hepatic biochemistries and clinical liver disease in patients with primary Sjögren's syndrome. Ann Hepatol. 2007; 6(3):150-5. View

Fox R . Sjögren's syndrome. Lancet. 2005; 366(9482):321-31. DOI: 10.1016/S0140-6736(05)66990-5. View

Ramos-Casals M, Nardi N, Brito-Zeron P, Aguilo S, Gil V, Delgado G . Atypical autoantibodies in patients with primary Sjögren syndrome: clinical characteristics and follow-up of 82 cases. Semin Arthritis Rheum. 2006; 35(5):312-21. DOI: 10.1016/j.semarthrit.2005.12.004. View

10.

Shiboski C, Shiboski S, Seror R, Criswell L, Labetoulle M, Lietman T . 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. Arthritis Rheumatol. 2016; 69(1):35-45. PMC: 5650478. DOI: 10.1002/art.39859. View

11.

Brito-Zeron P, Baldini C, Bootsma H, Bowman S, Jonsson R, Mariette X . Sjögren syndrome. Nat Rev Dis Primers. 2016; 2:16047. DOI: 10.1038/nrdp.2016.47. View

12.

Gelber A, Pillemer S, Baum B, Wigley F, Hummers L, Morris S . Distinct recognition of antibodies to centromere proteins in primary Sjogren's syndrome compared with limited scleroderma. Ann Rheum Dis. 2006; 65(8):1028-32. PMC: 1798261. DOI: 10.1136/ard.2005.046003. View

13.

Suzuki Y, Fujii H, Nomura H, Mizushima I, Yamada K, Yamagishi M . Impact of double positive for anti-centromere and anti-SS-a/Ro antibodies on clinicopathological characteristics of primary Sjögren's syndrome: a retrospective cohort study. Mod Rheumatol. 2017; 28(5):872-878. DOI: 10.1080/14397595.2017.1418164. View

14.

Lee K, Kang J, Lee J, Wen L, Park D, Kim T . Anti-centromere antibody-positive Sjögren's syndrome: A distinct clinical subgroup?. Int J Rheum Dis. 2015; 18(7):776-82. DOI: 10.1111/1756-185X.12684. View

15.

Shiboski S, Shiboski C, Criswell L, Baer A, Challacombe S, Lanfranchi H . American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken). 2012; 64(4):475-87. PMC: 3349440. DOI: 10.1002/acr.21591. View

16.

Thomson W, Chalmers J, Spencer A, Williams S . The Xerostomia Inventory: a multi-item approach to measuring dry mouth. Community Dent Health. 2000; 16(1):12-7. View

17.

Nakamura H, Kawakami A, Hayashi T, Iwamoto N, Okada A, Tamai M . Anti-centromere antibody-seropositive Sjögren's syndrome differs from conventional subgroup in clinical and pathological study. BMC Musculoskelet Disord. 2010; 11:140. PMC: 2902414. DOI: 10.1186/1471-2474-11-140. View

18.

Seror R, Bowman S, Brito-Zeron P, Theander E, Bootsma H, Tzioufas A . EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide. RMD Open. 2015; 1(1):e000022. PMC: 4613159. DOI: 10.1136/rmdopen-2014-000022. View

19.

Lee Y, Nam H, Chuang L, Kim K, Yang H, Kwon I . South Korean time trade-off values for EQ-5D health states: modeling with observed values for 101 health states. Value Health. 2009; 12(8):1187-93. DOI: 10.1111/j.1524-4733.2009.00579.x. View

20.

Takeshita M, Suzuki K, Kaneda Y, Yamane H, Ikeura K, Sato H . Antigen-driven selection of antibodies against SSA, SSB and the centromere 'complex', including a novel antigen, MIS12 complex, in human salivary glands. Ann Rheum Dis. 2019; 79(1):150-158. PMC: 6937410. DOI: 10.1136/annrheumdis-2019-215862. View